Teleflex Inc Stock Price, News & Analysis

Teleflex (NYSE: TFX) has announced its latest quarterly dividend declaration. The company's Board of Directors has approved a cash dividend of $0.34 per share of common stock. The dividend will be distributed on March 17, 2025, to shareholders who are on record as of the close of business on March 7, 2025.

Teleflex (NYSE: TFX) reported Q4 2024 revenues of $795.4 million, up 2.8% year-over-year, with adjusted diluted EPS of $3.89 compared to $3.38 in the prior year. Full-year 2024 adjusted revenue reached $3,061.1 million, up 2.9% from the previous year.

The company recorded a significant non-cash goodwill impairment charge of $240 million in the Interventional Urology unit, primarily due to subdued UroLift revenue growth expectations. For 2025 guidance, Teleflex projects adjusted constant currency revenue growth of 1.0% to 2.0% and adjusted diluted EPS of $13.95 to $14.35.

Two major strategic announcements were made: the planned acquisition of BIOTRONIK's Vascular Intervention business and the intention to separate Teleflex into two publicly traded companies. Additionally, the company plans to initiate a $300 million accelerated share repurchase program.

Teleflex (NYSE:TFX) announced that Chief Financial Officer Thomas E. Powell will retire effective April 1, 2025, after more than 13 years with the company. John R. Deren, currently Corporate Vice President and Chief Accounting Officer, will succeed as Executive Vice President and CFO effective April 2, 2025.

Powell will continue as a consultant through March 31, 2026, to ensure a smooth transition. Under his tenure, Teleflex achieved an 800 basis points increase in adjusted operating margin from 2012-2024. Deren, who joined Teleflex in 2013, brings over 30 years of financial management experience, having previously worked at PricewaterhouseCoopers, Rohm and Haas, Exelon Generation, and Trinseo.

Teleflex (NYSE:TFX) announced plans to separate into two independent publicly traded companies by mid-2026. The separation will be executed through a tax-free distribution of newly issued shares to shareholders.

The first company, RemainCo ($2.1B revenue in 2024), will focus on Vascular Access, Interventional, and Surgical businesses, targeting high-growth hospital-focused emergent markets. It's projected to deliver 6%+ constant currency revenue growth and double-digit EPS growth in the first year post-separation.

The second company, NewCo ($1.4B revenue in 2024), will comprise Urology, Acute Care, and OEM businesses. It's expected to generate low-single digit constant currency revenue growth with a mid-50% adjusted gross margin profile.

The separation aims to create two focused entities with simplified operating models, streamlined manufacturing footprints, and enhanced resource allocation. RemainCo will transition from 19 to 7 manufacturing facilities, with the remaining 12 transferring to NewCo.

Teleflex (NYSE:TFX) has announced a definitive agreement to acquire BIOTRONIK's Vascular Intervention business for approximately €760 million. The acquisition, expected to close by Q3 2025, will expand Teleflex's presence in the estimated $10 billion interventional cardiology and peripheral vascular market.

The acquired portfolio includes drug-coated balloons, drug-eluting stents, and other vascular intervention devices. In 2023, approximately 75% of revenues came from coronary interventions and 25% from peripheral interventional procedures. The business demonstrated a 5.4% constant currency revenue CAGR from 2022 to 2024 and is expected to generate approximately €91 million in revenues in Q4 2025.

Key products include the Pantera Lux Drug-Coated Balloon Catheter, PK Papyrus Covered Coronary Stent, and Orsiro Mission Drug Eluting Stent. The deal is expected to be approximately $0.10 accretive to adjusted earnings per share in the first year post-close.

Teleflex (NYSE: TFX) has announced its participation in the Raymond James & Associates 46th Annual Institutional Investors Conference. The event will take place at the JW Marriott Grande Lakes in Orlando, Florida, on Tuesday, March 4, 2025, at 3:25 p.m. (ET).

The company's management will deliver a presentation, which will be accessible to investors through a live audio webcast along with accompanying slides. Interested parties can access the presentation through the investor section of the Teleflex website at teleflex.com.

Teleflex (NYSE:TFX) has announced it will host a conference call to discuss its fourth quarter financial results and provide an operational update on Thursday, February 27, 2025, at 8:00 a.m. Eastern Time. Participants can pre-register to receive dial-in information, and the call will also be accessible via live audio webcast on teleflex.com.

An audio replay will be available starting at 11:00 am Eastern Time on the same day, accessible through the company's website or by telephone. The replay can be accessed by dialing 1 800 770 2030 (U.S. and Canada) or 1 609 800 9909 (other locations) with conference ID 69028.

Pulse Biosciences (PLSE) has appointed Jon Skinner as Chief Financial Officer, effective February 3, 2025. Skinner brings extensive healthcare sector experience, most recently serving as VP of FP&A and Investor Relations at Copeland. His prior roles include VP of Finance and Corporate Development at Imperative Care and VP of Finance – Interventional Urology at Teleflex, where he led 25 M&A transactions.

As part of his appointment, Skinner received inducement grants of options to purchase 300,000 shares at $20.93 per share. The options vest over four years, with half based on continuous employment and half tied to achieving product revenue and market capitalization milestones between $2 billion and $5 billion.

The appointment aims to support the company's operational excellence and commercialization of its CellFX nanosecond PFA Platform, which utilizes proprietary Nanosecond Pulsed Field Ablation technology.

Teleflex (NYSE: TFX) has secured a contract with Vizient, the largest provider-driven healthcare performance improvement company in the U.S., effective January 1, 2025. The agreement covers Teleflex's Central Venous Access Catheters and Arterial Catheters supply.

Vizient serves over 65% of U.S. acute care providers, including 97% of academic medical centers, representing more than $140 billion in annual purchasing volume. The contract enables Vizient provider-customers to access increased savings and pre-negotiated terms on Teleflex's vascular access products.

The agreement includes Arrowg+ard Blue Plus™ CVCs, which feature antimicrobial protection reducing Central Line-Associated Bloodstream Infections by 67-100%, Arrow™ ErgoPack™ Complete Systems, and Arrow™ Arterial Catheters and Catheterization Kits. These solutions help healthcare systems comply with practice recommendations, standardize vascular access products, and control infection-related costs.